Stability vs. Fluctuation in HS — How to Tell the Difference

The Quiet Period Problem

Most patients with HS have experienced quiet periods — stretches of time in which the condition seems better: fewer new lesions, less pain, a tentative return to activities that had been disrupted. These periods are not insignificant. They represent real reduction in the immediate impact of the disease, and the relief they bring — physical and psychological — is genuine.

But quiet periods in HS are frequently misread in ways that lead to consequential decisions. They are interpreted as evidence that the disease is resolving on its own, or that a recent change in diet or medication has produced lasting improvement, or that the condition has simply become less severe over time. On the basis of this interpretation, treatment efforts are reduced or discontinued — and then the disease returns, often at its previous level of activity or worse.

The quiet period was not resolution. It was fluctuation. And fluctuation is a feature of HS that is driven by the same internal architecture that drives the disease itself — not by a change in that architecture. Understanding the difference between fluctuation and genuine stability is one of the most practically useful distinctions in managing HS over time.

Why HS Fluctuates Without Genuine Change

HS fluctuates because its internal drivers are not constant. They are influenced by factors that change over time — hormonal cycles, stress load, dietary patterns, sleep quality, season — and as these factors shift, the degree to which they are activating the disease's drivers shifts with them. When multiple drivers are simultaneously at a lower point of activation, the disease appears quieter. When they converge at a higher point of activation, the disease flares.

This explains one of the most frustrating features of HS for patients: the apparent unpredictability of flares. Objectively, the flares are not unpredictable — they reflect the convergence of internal drivers at a threshold that generates lesion activity. But without understanding what those drivers are and what causes their activation levels to shift, the pattern appears random. A bad week at work. A disrupted diet during travel. A hormonal phase. Each of these shifts one or more drivers upward; when they combine, the threshold is crossed and a lesion forms. When they recede, the threshold is no longer being reached — and a quiet period follows.

The key insight is this: during the quiet period, the internal drivers that produce HS have not changed. They are temporarily at a lower point of activation. The architecture — gut dysfunction, hormonal imbalance, immune dysregulation — remains exactly as it was. The quiet period is not remission; it is the trough of the same fluctuation pattern that has always characterised the disease. The next convergence of drivers will produce the next flare. It is not a question of whether, only of when.

The Hormonal Cycle — A Visible Example of Fluctuation

For women with HS, the hormonal cycle makes fluctuation particularly visible. Many women experience a reliable pattern of flare activity in the days before menstruation — when progesterone is falling and oestrogen-to-androgen ratios shift in ways that activate the hormonal drivers of HS. After menstruation, as hormone levels stabilise in the follicular phase, activity often reduces. This is not improvement. It is the hormonal trough of a predictable fluctuation cycle. The disease is entirely unchanged internally; only the phase of the cycle has shifted.

This cycle is useful to understand because it makes explicit what fluctuation feels like from the inside: a reliable rhythm of better and worse that tracks an underlying biological pattern, not a change in the underlying biological state. Patients who understand this are far less likely to interpret the follicular-phase quiet as improvement that warrants reducing treatment — and far better placed to understand that the pre-menstrual flare is not a setback but a predictable expression of an unchanged internal driver.

What Genuine Stability Looks Like

Genuine stability in HS — stability that reflects actual internal change rather than temporary driver convergence at a low point — has a different character from fluctuation. The difference is visible not in any single period, but in the pattern over time.

Fluctuation produces a consistent oscillating pattern. Better periods followed by worse periods, with roughly similar amplitude over time. The quiet periods are real; so are the flares. Neither is improving relative to the other. Tracked over months, the pattern shows a horizontal trajectory: the disease is neither better nor worse, on average. It is fluctuating around a stable level of activity driven by a stable internal state.

Genuine stability produces a directional trajectory. Quiet periods become longer. Active periods become shorter and less severe. The amplitude of the oscillation decreases — not because the cycle disappears, but because the internal drivers that feed the peaks of the cycle are being corrected. Tracked over months, the pattern shows a downward trajectory in both frequency and severity, even if individual data points within that trajectory are non-linear.

This distinction is why tracking HS over months rather than weeks is essential for evaluating what is actually happening. Any individual week — particularly a quiet one — can be misread as evidence of resolution. The six-month picture is where the genuine signal emerges: is the pattern oscillating around a stable level of activity, or is it trending in a direction that reflects actual internal change?

When Suppression Creates the Appearance of Stability

A further complication is that some forms of treatment — particularly hormonal suppression and biologic agents — can reduce HS activity in ways that closely resemble genuine stability, but without producing the internal change that genuine stability requires. The disease appears quieter; the interval between episodes lengthens; the patient and physician may both interpret this as evidence of sustained improvement.

The test of whether this represents genuine stability or suppression-induced quiet is straightforward in principle, though the answer is often only apparent in retrospect: what happens when the suppressive treatment is withdrawn? If the disease returns promptly to its previous level of activity, the suppression was never producing genuine stability. It was producing pharmacological quiet — a useful and sometimes clinically necessary state, but one that does not reflect or produce any change in the internal drivers that were generating the disease before the suppressive treatment began.

This is not an argument against suppressive treatment in contexts where it is appropriate. In severe, rapidly progressing HS, suppression may be clinically necessary to prevent further structural damage while internal correction is being established. But it is an argument for understanding clearly what suppression is and is not producing — so that the distinction between "the treatment is working" and "the treatment is keeping the disease quiet" is never confused. The former changes the trajectory. The latter suspends it.

Reading Your Own Pattern

One of the most empowering things a patient with HS can do is learn to read their own pattern accurately. This requires tracking over sufficient time — not day by day, which produces noise, but at regular intervals of three to four weeks — and attending to the right markers.

The markers that reveal pattern most clearly are: interval length between new lesion initiations; average severity of episodes when they do occur; time from initiation to resolution; and the quality of quiet periods — whether they feel genuinely settled and systemic, or merely surface-quiet with background tension, tenderness, or the sense that something is building beneath the surface.

That last marker deserves specific attention. Patients with HS in genuine fluctuation often describe their quiet periods as having a specific quality: a sense of provisional calm rather than genuine ease. A background awareness of tenderness at familiar sites, even when no active lesion is present. A subclinical restlessness in the affected areas that experienced patients come to recognise as a precursor — not paranoia, but accurate pattern recognition. Quiet periods in genuine stability tend to feel different: more complete, more systemic, less fragile. The background tension is lower because the systemic inflammatory burden that sustains it is lower. The affected areas are not simply not expressing; they are genuinely less primed.

What Changes When the Internal State Changes

When genuine internal correction is occurring — when the gut is restoring its function, when hormonal balance is being re-established, when immune regulation is improving — the change in the quality of quiet periods is often one of the earliest and most reliable indicators. Patients frequently describe it as something like: "The quiet feels different. It doesn't feel like I'm waiting for the next one."

This shift in quality is not imaginary. It reflects a genuine reduction in the systemic inflammatory burden — which means the threshold for HS activity is higher, the background tension in affected tissue is lower, and the quiet is not merely the trough of a fluctuation cycle but the early expression of a changed internal state. The lesion-free interval that follows is not a gap between episodes. It is the beginning of a different relationship with the disease.

Distinguishing this from ordinary fluctuation requires time and honest pattern tracking. But when it is present, it is recognisable — and it is the most useful signal available that the direction of correction is genuine rather than suppressive. The disease is not being kept quiet. It is becoming quieter. These are different things, with different implications for what comes next.

The Practical Takeaway

The distinction between stability and fluctuation in HS is not abstract. It has direct practical implications for the decisions patients make about their care. A patient who understands fluctuation does not reduce their treatment effort during a quiet period — because they understand that the quiet does not reflect a change in what is driving the disease. A patient who understands genuine stability can recognise its markers and use them as a guide to when correction is consolidating — and when it still requires sustained support.

Both of these patterns — fluctuation and stability — are observable in the clinical picture of HS over time. Both require understanding, not just management. And the ability to distinguish between them is part of what allows treatment to be directed accurately: at what is actually happening internally, rather than at whatever the skin is expressing today.